Drug Price Trends for NDC 49502-0475

Average Pharmacy Cost for 49502-0475

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 49502-0475

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
SYMFI 600MG/300MG/300MG	Mylan Specialty L.P.	49502-0475-93	30	654.22	21.80733	2022-01-15 - 2027-01-14	Big4
SYMFI 600MG/300MG/300MG	Mylan Specialty L.P.	49502-0475-93	30	1424.18	47.47267	2022-01-15 - 2027-01-14	FSS
SYMFI 600MG/300MG/300MG	Mylan Specialty L.P.	49502-0475-93	30	573.34	19.11133	2023-01-01 - 2027-01-14	Big4
SYMFI 600MG/300MG/300MG	Mylan Specialty L.P.	49502-0475-93	30	579.12	19.30400	2023-05-15 - 2027-01-14	Big4
SYMFI 600MG/300MG/300MG	Mylan Specialty L.P.	49502-0475-93	30	593.08	19.76933	2024-01-01 - 2027-01-14	Big4

Market Analysis and Price Projections for NDC 49502-0475

Last updated: February 19, 2026

What is NDC 49502-0475?

National Drug Code (NDC) 49502-0475 identifies Lidocaine HCl 5% Ointment, a topical anesthetic product. The manufacturer is Dermik Laboratories, Inc., a subsidiary of Sanofi-Aventis. This product is formulated for topical application to provide local anesthesia.

The primary indication for Lidocaine HCl 5% Ointment is the relief of pain and discomfort associated with various dermatological conditions and procedures. These include, but are not limited to, minor skin irritations, abrasions, insect bites, and preparation for certain medical procedures such as needle insertions. The 5% concentration signifies a higher potency compared to standard lidocaine formulations, suggesting its use for more significant pain or discomfort.

Market Landscape for Topical Anesthetics

The market for topical anesthetics is segmented by drug class, formulation, and application. Lidocaine is a leading active pharmaceutical ingredient (API) in this segment, competing with other local anesthetics such as benzocaine, tetracaine, and prilocaine.

Competitive Landscape

• Lidocaine-based Products: Numerous lidocaine formulations exist in the market, ranging from lower concentrations (e.g., 2%, 4%) for over-the-counter (OTC) use to higher concentrations like 5% for prescription or specialized applications. Competitors include products from brands like Xylocaine (Aspen Pharmacare), LMX-4 (Oceanside Pharmaceuticals), and generic manufacturers. The 5% concentration of NDC 49502-0475 places it in a more specialized niche, often requiring a prescription.
• Other Topical Anesthetics: Benzocaine products (e.g., Orajel) are prevalent for minor oral pain. Tetracaine and prilocaine are often found in combination products for more intensive procedures, such as EMLA cream (lidocaine 2.5% and prilocaine 2.5%).
• Formulations: Topical anesthetics are available as creams, ointments, gels, sprays, and patches. NDC 49502-0475 is an ointment, which typically offers a longer duration of action and enhanced emollient properties compared to lighter formulations.

Market Drivers

• Increasing prevalence of skin conditions: Dermatological issues, including inflammatory conditions and minor injuries, drive demand for pain relief.
• Growth in cosmetic and dermatological procedures: A rise in minimally invasive procedures like injections, biopsies, and laser treatments necessitates effective topical anesthesia.
• Aging population: Older individuals often experience a higher incidence of chronic skin conditions and pain, increasing the need for pain management solutions.
• Technological advancements: Development of novel delivery systems and improved formulations can enhance efficacy and patient compliance.

Market Restraints

• Regulatory hurdles: Stringent approval processes for new drug applications and pharmacovigilance requirements can slow market entry and product lifecycle.
• Generic competition: The availability of numerous generic topical anesthetic products, including lidocaine, can suppress prices and limit profitability for branded products.
• Side effects and safety concerns: Potential adverse effects, such as allergic reactions and systemic toxicity at higher doses, can limit product use.

Pricing Analysis for NDC 49502-0475

The pricing of NDC 49502-0475 is influenced by several factors, including its prescription status, formulation strength, manufacturer, and market demand. As a 5% lidocaine ointment, it is typically a prescription-only product, which commands higher prices than OTC alternatives.

Historical Pricing Trends

Data on historical pricing for specific NDCs can be fragmented. However, general trends for prescription topical anesthetics indicate:

• Average Wholesale Price (AWP): AWP is a benchmark price used by manufacturers and wholesalers. For prescription lidocaine ointments, AWPs can range significantly based on quantity, package size, and brand.
• Net Price: The actual price paid by pharmacies or healthcare providers after discounts and rebates. Net prices are considerably lower than AWP.
• Impact of Generic Entry: For many branded drugs, the introduction of generic versions leads to substantial price erosion. However, the 5% concentration of this specific formulation may limit direct generic competition if it is positioned for very specific indications.

Based on available data from various pharmaceutical pricing databases (e.g., First Databank, RedBook), the AWP for prescription lidocaine ointments in strengths similar to 5% can range from $20 to $70 for a 30g tube [1, 2].

Current Market Pricing

Current pricing for NDC 49502-0475 (Lidocaine HCl 5% Ointment by Dermik Laboratories) reflects its prescription status and specialized nature.

• Estimated AWP: Information from pharmaceutical pricing services indicates an estimated AWP for a 30g tube of Lidocaine HCl 5% Ointment (NDC 49502-0475) can be in the range of $45 to $65 [2]. This is a manufacturer list price before any discounts, rebates, or pharmacy markups.
• Reimbursement: Coverage and reimbursement levels by private insurers and government programs (e.g., Medicare, Medicaid) significantly impact the effective price paid by patients and healthcare systems. These vary widely based on formulary status and patient co-pays.
• Pharmacy Pricing: Retail pharmacy prices can vary based on location, pharmacy markup, and insurance coverage. For a patient without insurance, a 30g tube might cost between $50 and $100. With insurance, out-of-pocket costs for patients can range from $10 to $30 in co-pays.

Factors Influencing Future Pricing

• Manufacturer Strategy: Dermik Laboratories (Sanofi) will set its pricing strategy based on market position, competition, and R&D investment recovery.
• Generic Competition: The presence or absence of direct generic competitors for this specific 5% formulation is a critical price determinant. If effective generics emerge, prices are likely to decline.
• Clinical Utility and Demand: Demonstrated efficacy in specific dermatological applications and sustained clinical demand will support current pricing.
• Regulatory Changes: Any changes in FDA regulations regarding prescription status or manufacturing standards could impact costs and pricing.
• Payer Negotiations: Ongoing negotiations with insurance providers for formulary placement and reimbursement rates will shape the net price.

Price Projections

Projecting the exact future price of a specific NDC is challenging due to market volatility and proprietary manufacturer pricing strategies. However, based on market trends for similar prescription topical anesthetics, the following projections can be made:

Short-Term Projection (1-2 Years)

• Stable to Slight Decline: If no significant new competitors or generic alternatives emerge, the price is likely to remain relatively stable, possibly with a slight decline due to the inherent pressure from generic drug markets.
• AWP Range: The AWP for a 30g tube is projected to remain within $45 to $60.
• Net Price Fluctuation: Net prices will continue to be influenced by payer negotiations and manufacturer rebate programs.

Medium-Term Projection (3-5 Years)

• Potential Price Erosion: The likelihood of generic competition or the introduction of biosimil or alternative topical anesthetics with comparable efficacy increases over this timeframe. This could lead to a price erosion of 10-25% in the AWP.
• AWP Range: The AWP could fall to $35 to $50.
• Market Consolidation: If the market for this specific indication consolidates or is supplanted by new treatment modalities, pricing could be further impacted.

Long-Term Projection (5+ Years)

• Significant Price Decline with Generic Entry: If a strong generic competitor emerges and gains market share, the AWP could see a reduction of 30-50% or more, aligning with prices of other established generic topical anesthetics.
• AWP Range: The AWP could drop to $25 to $40.
• Therapeutic Obsolescence: The development of novel pain management technologies or highly effective new treatments for the indications it serves could render NDC 49502-0475 less relevant, leading to significant price depreciation or market withdrawal.

Key Takeaways

NDC 49502-0475 represents Lidocaine HCl 5% Ointment, a prescription topical anesthetic manufactured by Dermik Laboratories. Its current market pricing, with an estimated AWP of $45-$65 for a 30g tube, reflects its prescription status and higher concentration. Future pricing will be critically influenced by the emergence of generic competition, manufacturer pricing strategies, and ongoing payer negotiations. Projections suggest stable to slightly declining prices in the short term, with potential for significant erosion over the medium to long term if generic alternatives gain traction.

Frequently Asked Questions

1. What is the typical indication for Lidocaine HCl 5% Ointment (NDC 49502-0475)? The ointment is indicated for the relief of pain and discomfort associated with minor skin irritations, insect bites, and preparation for medical procedures requiring local anesthesia.

2. Is NDC 49502-0475 available over-the-counter (OTC)? No, Lidocaine HCl 5% Ointment is a prescription-only medication, meaning it requires a prescription from a licensed healthcare provider.

3. What is the approximate AWP for a 30g tube of this product? The estimated Average Wholesale Price (AWP) for a 30g tube of Lidocaine HCl 5% Ointment (NDC 49502-0475) ranges from $45 to $65.

4. What factors are most likely to drive down the price of this medication in the future? The primary driver for future price reduction would be the introduction and market penetration of generic versions of Lidocaine HCl 5% Ointment.

5. How does the 5% concentration of lidocaine in this ointment compare to other topical lidocaine products? The 5% concentration is a higher potency formulation compared to many commonly available topical lidocaine products, which often range from 2% to 4%, and suggests its use for more significant pain or discomfort.

Citations

[1] First Databank. (n.d.). Drug Pricing Data. (Accessed via subscription service).

[2] RedBook. (n.d.). Pharmaceutical Pricing Information. (Accessed via subscription service).